OncoMatch/Clinical Trials/NCT06532539
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Is NCT06532539 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Paclitaxel and Cisplatin and Cadonilimab for endometrial neoplasms.
Treatment: Paclitaxel and Cisplatin · Cadonilimab — The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial carcinoma. The main questions it aims to answer are: 1. Does the combination therapy improve the overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety in participants? 2. What are the predictive biomarkers of treatment efficacy, and how can this information better guide the use of immune-oncology drugs in combination therapy? Participants will: * Receive cadonilimab, paclitaxel, cisplatin, and radiation therapy according to a specified protocol. * Visit the clinic for regular checkups and tests throughout the treatment period. * Be monitored for and have records kept of ORR, PFS, DCR, OS, and safety. * Provide hematologic and tissue samples to explore biomarkers. This study will help determine if this combination therapy can become a new standard of care for patients with locally recurrent and oligometastatic endometrial carcinoma, as well as identify biomarkers to better guide treatment strategies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any anti-tumor therapy — initial treatment
locally recurrent or oligometastatic endometrial cancer after initial treatment
Cannot have received: radiotherapy
Exception: allowed if completed >4 weeks (or 5 drug half-lives, whichever is longer) before first dose
Subjects who have received radiotherapy...within 4 weeks (or 5 drug half-lives, whichever is longer) prior to the first dose of the study drug
Cannot have received: chemotherapy
Exception: allowed if completed >4 weeks (or 5 drug half-lives, whichever is longer) before first dose
Subjects who have received...chemotherapy...within 4 weeks (or 5 drug half-lives, whichever is longer) prior to the first dose of the study drug
Cannot have received: hormone therapy
Exception: allowed if completed >4 weeks (or 5 drug half-lives, whichever is longer) before first dose
Subjects who have received...hormone therapy...within 4 weeks (or 5 drug half-lives, whichever is longer) prior to the first dose of the study drug
Cannot have received: molecular targeted therapy
Exception: allowed if completed >4 weeks (or 5 drug half-lives, whichever is longer) before first dose
Subjects who have received...molecular targeted therapy within 4 weeks (or 5 drug half-lives, whichever is longer) prior to the first dose of the study drug
Cannot have received: surgery
Exception: allowed if completed >4 weeks (or 5 drug half-lives, whichever is longer) before first dose
Subjects who have received...surgery...within 4 weeks (or 5 drug half-lives, whichever is longer) prior to the first dose of the study drug
Cannot have received: other investigational drugs or similar therapeutic agents
Exception: allowed if completed >4 weeks before first dose
Subjects who have used other investigational drugs or similar therapeutic agents within 4 weeks prior to the first dose
Lab requirements
Blood counts
Hemoglobin ≥80 g/L; ANC ≥1.5×10^9/L; Platelet count ≥50×10^9/L
Kidney function
serum creatinine ≤1.5×ULN; if >1.5×ULN, CrCl ≥50 mL/min
Liver function
ALT and AST ≤2.5×ULN, total serum bilirubin ≤1.5×ULN, ALP ≤3×ULN, serum albumin ≥30 g/L
Cardiac function
LVEF >50%
Normal major organ function (within 7 days before enrollment), meeting the following criteria: ... ALT and AST ≤2.5×ULN, total serum bilirubin ≤1.5×ULN, ALP ≤3×ULN, serum albumin ≥30 g/L; serum creatinine ≤1.5×ULN; if serum creatinine is >1.5×ULN, creatinine clearance (CrCl) ≥50 mL/min; Hemoglobin (HB) ≥80 g/L; ANC ≥1.5×10^9/L; Platelet count (PLT) ≥50×10^9/L; LVEF >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify